Cybin, Inc. (CYBN)

NYSEAMERICAN: CYBN · IEX Real-Time Price · USD
0.623
+0.040 (6.81%)
Oct 4, 2022 4:00 PM EDT - Market closed
6.81%
Market Cap 93.34M
Revenue (ttm) n/a
Net Income (ttm) -51.14M
Shares Out 149.83M
EPS (ttm) -0.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 820,860
Open 0.630
Previous Close 0.583
Day's Range 0.584 - 0.630
52-Week Range 0.390 - 2.355
Beta n/a
Analysts Buy
Price Target 4.90 (+686.5%)
Earnings Date Aug 12, 2022

About CYBN

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada. [Read more...]

Industry Biotechnology
Founded 2019
Employees 50
Stock Exchange NYSEAMERICAN
Ticker Symbol CYBN
Full Company Profile

Financial Performance

Financial numbers in CAD Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for CYBN stock is "Buy." The 12-month stock price forecast is 4.9, which is an increase of 686.52% from the latest price.

Price Target
$4.9
(686.52% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics™, is pleased to announce ...

1 week ago - Business Wire

Cybin to Participate in Upcoming Scientific and Investor Conferences

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing Psychedelics to TherapeuticsTM, is pleased to announce...

1 week ago - Business Wire

Cybin Achieves Research and Development Milestones Ahead of Projected Timelines

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, announced that it ha...

2 weeks ago - Business Wire

Cybin Announces Final Adelia Milestone Achievement

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that...

1 month ago - Business Wire

7 Psychedelics Stocks to Buy for a Big Drug Boom

Psychedelics stocks are becoming increasingly mainstream, in part due to changing social attitudes. Psychedelic drugs “are a loosely grouped class of drugs that are able to induce altered thoughts and s...

1 month ago - InvestorPlace

Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, is pleased to announ...

1 month ago - Business Wire

Cybin to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM” is pleased to announc...

1 month ago - Business Wire

Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, and its partner Clini...

1 month ago - Business Wire

Cybin Announces Results of Shareholders' Meeting

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, is pleased to announ...

1 month ago - Business Wire

3 Best Psychedelic Stocks to Buy Now

The incredible healing properties of psychedelics are being discovered with every passing day. Their potential is massive and can flip the script for those struggling with mental health disorders.

Other symbols: CMPSMNMD
1 month ago - InvestorPlace

CORRECTING and REPLACING Cybin Announces Up to USD$35 Million At-The-Market Equity Program

TORONTO--(BUSINESS WIRE)--First paragraph, first sentence of release should read: Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progress...

1 month ago - Business Wire

Cybin Announces Up to USD$35 Million At-The-Market Equity Program

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, announced today th...

1 month ago - Business Wire

Cybin Inc. Reports First Quarter Financial Results and Recent Business Highlights

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today reported unaud...

1 month ago - Business Wire

Cybin to Present at the Canaccord Genuity 42nd Annual Growth Conference

TORONTO, Ontario--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM” is pleased t...

2 months ago - Business Wire

Cybin Announces Date of Annual Meeting of Shareholders

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM” announced today that ...

2 months ago - Business Wire

Bull Of The Day: Cybin (CYBN)

Instead of a hangover, the side effect from this treatment has been described as an "after glow."

2 months ago - Zacks Investment Research

Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2a Trial Evaluating CYB003 for the Treatment of ...

EATONTOWN, N.J.--(BUSINESS WIRE)--Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug developme...

2 months ago - Business Wire

Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that,...

2 months ago - Business Wire

Cybin (CYBN) Up on FDA Clearance of IND for CYB003 in MDD

Cybin (CYBN) receives a "may proceed letter" and IND application clearance from the FDA for a phase I/IIa study evaluating CYB003 for potential treatment of major depressive disorder. Shares up.

3 months ago - Zacks Investment Research

Cybin Announces Additional Adelia Milestone Achievement

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that...

3 months ago - Business Wire

Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of M...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that it h...

3 months ago - Business Wire

Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today reported audit...

3 months ago - Business Wire

Cybin to Present at the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM” is pleased to announc...

3 months ago - Business Wire

Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatm...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that i...

3 months ago - Business Wire

Cybin Acquires DMT Clinical Study from Entheon Biomedical

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that, thr...

3 months ago - Business Wire